ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the Benzinga Small Cap Conference on Thursday, May 13, 2021 at 11:30am ET (8:30am PT). ChromaDex CEO, Rob Fried, will also be presenting on a panel in the Transformative Healthcare track, entitled “Investing in Longevity Science: The New Drugs & Therapies Designed to Prolong Your Lifespan.” The panel is scheduled for Thursday, May 13, 2021 at 1:20pm ET.
The Global Small Cap Conference is a day dedicated to bridging the gap between Small Cap companies, investors and traders. The event will have multiple days of networking and education in a virtual setting.
A webcast of the company presentation will be posted under the investor relations section of ChromaDex’s website at www.chromadex.com, or can be accessed at https://investors.chromadex.com/events-and-presentations/default.aspx. A replay of the presentation will be available following the event.
To learn more about small-cap innovation and investing at the Benzinga Global Small Cap Conference, click here.
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen® available at www.truniagen.com and through partnerships with global retailers and distributors. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
Benzinga is a leading financial media company dedicated to making information easier to consume. Benzinga's news desk is constantly breaking stories and moving billions of dollars of market capitalization through its real-time news tool, Benzinga Pro. Benzinga's original content is syndicated to 70 partner websites including Yahoo! Finance MSN, CNNMoney, Fox Business and MarketWatch.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as amended, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
Brianna Gerber, Vice President of FP&A and Investor Relations
949-419-0288 ext. 127